Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.

Abstract

FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation-positive acute myeloid leukemia (AML) has a poor prognosis. We report the first case of successful bridge therapy of novel FLT3 inhibitor, quizartinib, to umbilical cord blood stem cell transplantation for FLT3-ITD-positive AML-primary induction failure patients with central nervous system involvement.

• Authors: Makiko Suga, Kentaro Fukushima, Tomoaki Ueda, Yasuyuki Arai, Shunsaku Nakagawa, Yosuke Minami, Jun Toda, Akihisa Hino, Jiro Fujita, Takafumi Yokota, Naoki Hosen
• Journal: Clinical case reports (Clin Case Rep) Vol. 10 Issue 2 Pg. e05384 (Feb 2022) ISSN: 2050-0904 [Print] England
• PMID: 35140970 (Publication Type: Case Reports)
• Copyright: © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.